Acute Lymphoblastic Leukemia Clinical Trial
Official title:
Computerized Intervention for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors
Children treated for a brain tumor (BT) or acute lymphoblastic leukemia (ALL) show elevated rates of working memory impairment. Working memory (WM) is the ability to hold and manipulate information online; for example, when an individual mentally rehearses a phone number in order to dial it without writing it down. A computer-based working memory intervention has been successful in children diagnosed with ADHD and stroke survivors. Individuals participating in the intervention showed improvements on working memory measures as well as more complex problem solving skills. Neuroimaging (brain scans) conducted before and after training showed changes in brain activation suggestive of underlying changes in brain systems that support working memory. This study investigates the effectiveness of this computer-based working memory intervention for childhood cancer survivors.
Status | Completed |
Enrollment | 128 |
Est. completion date | November 2013 |
Est. primary completion date | February 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 8 Years to 16 Years |
Eligibility |
Inclusion Criteria for Screening Phase: - Received CNS-directed treatment (intrathecal chemotherapy or cranial irradiation) for a BT or ALL - Infratentorial tumor location (for the BT cohort) - Off treatment for at least one year with no evidence of recurrent or progressive disease - Age 8-16 years inclusive at the time of enrollment - English as the primary language - Research participant and one parent willing to participate and provide consent/assent according to institutional guidelines Exclusion Criteria for Screening Phase - Significant impairment in global intellectual functioning (estimated or full scale IQ < 70 based on standardized testing routinely conducted on primary treatment protocols) - History of CNS injury/disease predating or unrelated to cancer diagnosis - Documented ADHD predating cancer diagnosis - Treatment with psychostimulant or psychotropic medication within two weeks of study participation - Major sensory or motor impairment that would preclude valid cognitive testing secondary to inability to complete study procedures (e.g., blindness, paresis, poorly controlled seizures/photosensitive epilepsy, psychosis) Inclusion Criteria for Intervention Phase - Signed screening consents and has undergone screening - Fully evaluable psychological testing results (including IQ > or = 70) - Age-scaled score on Digit Span, Letter-Number Sequencing or Spatial Span < 7 OR at least one standard deviation below IQ score - Training aide is available to participate in required sessions - Participant and training aide demonstrate computer proficiency - Participant has access to or will be provided a laptop or home computer with internet connection and speakers - Participant willing to participate in required aspects of computerized intervention - Participant is able to take part in fMRI without sedation Exclusion Criteria for Intervention Phase - Major psychological condition that would preclude completion of protocol intervention (e.g., significant oppositionality, autism spectrum disorder, severe anxiety or depressive symptoms) - Orthodontic appliances that cause MRI distortion or signal loss outside the mouth and sinus area |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
Lead Sponsor | Collaborator |
---|---|
St. Jude Children's Research Hospital | American Cancer Society, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | This study will measure working memory, attention and executive functions | Participants in the working memory intervention will demonstrate significantly greater improvement from pre- to immediate post-intervention on performance- and rater-based measures of working memory relative to childhood cancer survivors placed on an intervention waitlist. | Baseline, 10 weeks, and 6 months | No |
Secondary | The study will measure the maintenance of improvements on measures of working memory, attention and executive functions | The improvements will be evaluated at six months following participation in the computer-based intervention program. | 6 months. | No |
Secondary | This study will examine the neural correlates of working memory before and immediately after intervention | This objective will use fMRI to examine the neural correlates of working memory before and immediately after intervention. | Baseline and 10 weeks. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT05772000 -
Clinical Significance of Occult Central Nervous System Localization
|
||
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT03114865 -
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06308588 -
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT05579132 -
A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT06195891 -
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Withdrawn |
NCT02815059 -
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
|
Phase 1 | |
Completed |
NCT00390793 -
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT04488237 -
Vitamin D and Methotrexate Adverse Effects
|
||
Completed |
NCT02544438 -
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 |